Advanced search
Publication Cover
Current Medical Research and Opinion Volume 20, 2004 - Issue 12
Submit an article Journal homepage
134
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs*

D. J. Watson Epidemiology, Merck Research Laboratories, West Point, PA 19486, USACorrespondence[email protected]
,
J. A. Bolognese Clinical Biostatistics, Merck Research Laboratories, Rahway, NJ, 07065, USA
,
C. Yu Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
,
D. Krupa Clinical Biostatistics, Merck Research Laboratories, Rahway, NJ, 07065, USA
&
S. Curtis Clinical Research, Merck Research Laboratories, Rahway, NJ, 07065, USA
Pages 1899-1908 | Accepted 07 Oct 2004, Published online: 10 Nov 2004

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Winnie W. Nelson, Xue Song, Erin Thomson, David M. Smith, Craig I. Coleman, C.V. Damaraju & Jeffrey R. Schein. (2015) Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Current Medical Research and Opinion 31:10, pages 1831-1840.
Read now
Anthony Sebba. (2008) Efficacy and safety of etoricoxib in the treatment of osteoarthritis. Expert Review of Clinical Pharmacology 1:3, pages 345-355.
Read now
Alan Matsumoto, Agustin Melian, Arvind Shah & Sean P. Curtis. (2007) Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. Current Medical Research and Opinion 23:9, pages 2259-2268.
Read now
Peter Brooks & Paul Kubler. (2006) Etoricoxib for arthritis and pain management. Therapeutics and Clinical Risk Management 2:1, pages 45-57.
Read now
Werner Kiefer & Gerd Dannhardt. (2005) COX-2 inhibition and pain management: a review summary. Expert Review of Clinical Immunology 1:3, pages 431-442.
Read now

Articles from other publishers (13)

T. M. Ostroumova. (2021) Post-release of the symposium «How to Deal with Pain in the 21st Century? Expert Opinions» (November 8, 2021, XII Interdisciplinary International Congress «Manage Pain»). Neurology, Neuropsychiatry, Psychosomatics 13:6, pages 147-152.
Crossref
A. E. Karateev. (2021) Initial drug prescription in outpatient department: principal approach. Modern Rheumatology Journal 15:3, pages 91-97.
Crossref
I. S. Dydykina, P. S. Kovalenko & D. M. Kudinsky. (2021) Etoricoxib for generalized osteoarthritis. Case report. Modern Rheumatology Journal 15:1, pages 111-118.
Crossref
A. E. Karateev. (2020) The therapeutic potential of etoricoxib in clinical practice. Modern Rheumatology Journal 14:1, pages 108-117.
Crossref
A. E. Karateev, A. M. Lila, I. S. Dydykina, P. R. Kamchatnov, S. O. Mazurenko, M. V. Naprienko, D. S. Novikova, O. P. Ostroverkhov & M. V. Pchelintsev. (2018) Personalization of the use of non-steroidal anti-inflammatory drugs for musculoskeletal diseases. Resolution on the results of the Meeting of Experts of December 13, 2017. Medical Council:18, pages 76-84.
Crossref
B. Guruprasad, Priyanka Chaudhary, Tenzin Choedon & Vijay L. Kumar. (2014) Artesunate Ameliorates Functional Limitations in Freund’s Complete Adjuvant-Induced Monoarthritis in Rat by Maintaining Oxidative Homeostasis and Inhibiting COX-2 Expression. Inflammation 38:3, pages 1028-1035.
Crossref
Peter Bytzer. (2010) Dyspepsia as an adverse effect of drugs. Best Practice & Research Clinical Gastroenterology 24:2, pages 109-120.
Crossref
Michiel W. van der Linden, Sabine Gaugris, Ernst J. Kuipers, Myrthe P. P. van Herk‐Sukel, Bart J. F. van den Bemt, Shuvayu S. Sen & Ron M. C. Herings. (2009) COX‐2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiology and Drug Safety 18:10, pages 880-890.
Crossref
Katherine F. Croom & M. Asif A. Siddiqui. (2009) Etoricoxib. Drugs 69:11, pages 1513-1532.
Crossref
Jules I. Schwartz, Nancy G. B. Agrawal, Uma A. Kher, Marina DeSmet, Paul F. CavanaughJrJr, Michel Guillaume, David L. Ebel, Shelia A. Merschman & John A. Wagner. (2007) Lack of Effect of Antacids on Single-Dose Pharmacokinetics of Etoricoxib. The Journal of Clinical Pharmacology 47:10, pages 1342-1346.
Crossref
J??rgen Sch??lmerich. (2006) Nonsteroidal Anti-inflammatory Drugs Versus Selective COX-2 Inhibitors in the Upper Gastrointestinal Tract. Journal of Cardiovascular Pharmacology 47:Supplement 1, pages S67-S71.
Crossref
J??rgen N??sdal & Kurt Brown. (2006) NSAID-Associated Adverse Effects and Acid Control Aids to Prevent Them. Drug Safety 29:2, pages 119-132.
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:8, pages i-xii.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.